Isolation and Characterization of Lung Cancer Initiating Cells PDF Download

Author: Giulia Bertolini
Publisher:
ISBN:
Category : Lungs
Languages : en
Pages :

View

Book Description

Author: Kit-man Wong (Sunny)
Publisher:
ISBN:
Category : Cancer cells
Languages : en
Pages : 310

View

Book Description

Author: Kit-Man Sunny Wong
Publisher: Open Dissertation Press
ISBN: 9781361302170
Category :
Languages : en
Pages :

View

Book Description
This dissertation, "Isolation and Characterization of Cancer Stem Cells in Non-small Cell Lung Cancer" by Kit-man, Sunny, Wong, 王傑民, was obtained from The University of Hong Kong (Pokfulam, Hong Kong) and is being sold pursuant to Creative Commons: Attribution 3.0 Hong Kong License. The content of this dissertation has not been altered in any way. We have altered the formatting in order to facilitate the ease of printing and reading of the dissertation. All rights not granted by the above license are retained by the author. Abstract: Tumor heterogeneity has long been observed and recognized as a challenge to cancer therapy. The cancer stem cell (CSC) model is one of the hypotheses proposed to explain such a phenomenon. A specific cancer stem cell marker has not been determined for non-small cell lung cancers (NSCLC), preventing the definitive evaluation of whether the biology of NSCLC is governed by the CSC model. This study aimed to analyze the expression of candidate CSC markers and using the identified putative marker, to isolate CSC and determine the applicability of the CSC model in NSCLC. The expression or activities of four putative stem cell markers, CD24, CD44, CD133 and aldehyde dehydrogenase 1 (ALDH1) were measured by flow cytometry in eight NSCLC cell lines before and after chemotherapy for 24 hours. Markers with increased expression after treatment were considered potential CSC markers and used for isolating tumor cell subpopulations from the untreated cell lines by fluorescence-activated cell sorting (FACS). Confirmatory analyses using widely acceptable methodology were performed to test for CSC properties in the marker+ and marker- subpopulations. Isolated subpopulations were further characterized by functional and phenotypic studies. Flow cytometry showed amongst the 4 markers, only ALDH1 expression was significantly enhanced by chemotherapeutic treatment, suggesting ALDH1 could be a CSC marker. Untreated ALDH1+ cells formed significantly more and larger cell spheres in non-adherent, serum-free conditions than ALDH1- cells. Likewise, higher in vitro tumorigenic ability was observed in ALDH1+ subset using colony formation assay. Furthermore, a higher resistance to cytotoxic drugs was observed in ALDH1+ compared to ALDH1- cells. In vivo studies also showed ALDH1+ cells showed higher tumorigenicity than ALDH1- cells; as few as 2,500 ALDH1+ cells formed tumor in SCID mice which were serially transplantable to 2nd and 3rd recipients, while no tumor was formed from ALDH- cells with even ten times the number of cells. Also, expression analysis revealed higher expression of the pluripotency genes, OCT4, NANOG, BMI1 and SOX9, in ALDH1+ cells. In view of previous studies reporting CD44 as a CSC marker in lung cancer, double marker selection of putative CSC was performed to compare ALDH1+CD44+ and ALDH1-CD44+ subpopulations. Results of the spheroid body formation assay and cisplatin treatment experiments revealed the ALDH1+CD44+ subpopulation possessed higher self-renewal ability and chemo-resistance. Cell migration and invasion assays showed differences between the ALDH1+CD44+ and ALDH1- CD44+ subpopulations. The significance of these observations require further investigation. In conclusion, the result showed that ALDH1 could be a marker for NSCLC stem cells as evidenced by enhanced self-renewal and differentiation abilities in ALDH1+ subpopulation. Furthermore, this study observed the presence of at least two potential stem cell subpopulations in NSCLC cells with differential selfrenewal, chemotherapy resistance and cell mobility properties. Further investigations are required to validate th

Author: 吳采蓉
Publisher:
ISBN:
Category :
Languages : en
Pages : 0

View

Book Description

Author: Venkat Sundar Gadepalli
Publisher:
ISBN:
Category : Lungs
Languages : en
Pages :

View

Book Description

Author: Koji Okudela
Publisher: Nova Biomedical Books
ISBN: 9781617282959
Category : Cancer cells
Languages : en
Pages : 0

View

Book Description
Of the many markers for cancer stem cells (CSCs) in lung cancer reported to date, the cell surface antigen CD133, nuclear ß-catenin accumulation, the side population phenotype, and high aldehyde dehydrogenase (ALDH) activity seem to be most reliable. This book reviews the results of studies on lung CSCs and discusses the significance of these markers from a biological, pathological, and clinical viewpoint. Twenty-seven lung cancer cell lines (nine small cell lung carcinoma (SCLC) cell lines and eighteen non-small cell lung carcinoma (NSCLC) cell lines) were examined for mRNA and protein expression and fractions of cells with activity.

Author: Surajit Pathak
Publisher: Springer Nature
ISBN: 9811551200
Category : Medical
Languages : en
Pages : 369

View

Book Description
This book discusses the recent developments in the therapeutic implications of cancer stem cells for the effective diagnosis, prognosis, and treatment of cancer. It summarizes the various stem cells of common cancers including colon, pancreas, lungs, prostate, melanoma, and glioblastoma, and reviews the potential role of cancer stem cells in tissue aggressiveness, examining the functional contribution of cancer stem cells in the establishment and recurrence of cancerous tumors. Further, it explores the potential of cancer stem cells as novel therapeutic targets for the treatment and prevention of tumor progression. The book also discusses the various approaches for detecting, isolating, and characterizing different cancer stem cells and signaling pathways that control their replication, survival, and differentiation. Lastly, it explores the key features and mechanisms of drug resistance, chemo-resistance, and radio-resistance in cancer stem cells to improve therapeutic rationale.

Author: Mark Jesus M. Magbanua
Publisher: Springer
ISBN: 3319559478
Category : Medical
Languages : en
Pages : 304

View

Book Description
Numerous studies have shown that elevated levels of circulating tumor cells (CTCs) in blood of cancer patients are associated with poor response to treatment and inferior survival probabilities. Despite this clinical significance, the molecular biology of CTCs remains poorly understood. The paucity in molecular information can be attributed to the tremendous technical challenges involved in isolating these extremely rare cells. Recent technological advancements in rare-cell technology, however, have allowed for the reliable enrichment and isolation of CTCs. Consequently, the use of recently developed molecular approaches —e.g., multiplexed QPCR, microarray, and next generation sequencing analyses— to profile CTCs have provided novel insights into the molecular makeup of these tumor cells. This book discusses approaches for enrichment and isolation of CTCs as well as recent advances in comprehensive molecular profiling of CTCs using cutting-edge omics technology.

Author: Rahul Jandial
Publisher: CRC Press
ISBN: 9781587066597
Category : Medical
Languages : en
Pages : 312

View

Book Description
Most cancer deaths are a result of metastasis. The spread of a primary tumor to colonize neighboring and distant organs is the relentless endgame that defines the neoplastic process. Patients who have been diagnosed with cancer are treated to prevent both the recurrence of the tumor at the site of origin and metastasis that would re-stage them as advanced stage IV cancer. Historically and still with some types of cancer, stage IV is perceived by patients as “terminal.” Fortunately, recent molecular therapies have extended the lives of patients with advanced cancer and reassuringly people living with metastatic disease increasingly visit our clinics. What is the path forward? Given that the consilience of science and medicine is a dynamic art from which therapies arise, it would be misguided to consider any single work adequate at capturing the horizon for research. So with humility we constructed this text as primer for scientists. It begins with a broad introduction to the clinical management of common cancers. This is intended to serve as a foundation for investigators to consider when developing basic science hypotheses. Unquestionably, medical and surgical care of cancer patients reveals biology and dictates how novel therapeutics will ultimately be evaluated in clinical trials. The second section of this text offers provocative and evolving insights that underscore the breadth of science involved in the elucidation of cancer metastasis biology. The text concludes with information that integrates scientific and clinical foundations to highlight translational research. This book serves as a framework for scientists to conceptualize clinical and translational knowledge on the complexity of disease that is metastatic cancer.

Author: United States. Public Health Service. Office of the Surgeon General
Publisher:
ISBN:
Category : Government publications
Languages : en
Pages : 728

View

Book Description
This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.